Capstone Investment Advisors, LLC Viking Therapeutics, Inc. Transaction History

Capstone Investment Advisors, LLC

  • $29.5 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024
BUY
$17.4 - $94.5 $716,079 - $3.89 Million
41,154 New
41,154 $3.37 Million
Q1 2020

May 15, 2020
SELL
$3.45 - $7.95 $131,376 - $302,736
-38,080 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$6.38 - $8.73 $13,398 - $18,333
-2,100 Reduced 5.23%
38,080 $305,000
Q3 2019

Nov 14, 2019
SELL
$6.55 - $8.6 $260,821 - $342,452
-39,820 Reduced 49.78%
40,180 $276,000
Q2 2019

Aug 14, 2019
BUY
$7.67 - $10.63 $613,600 - $850,400
80,000 New
80,000 $664,000

Others Institutions Holding VKTX

# of Institutions
442
Shares Held
63.3M
Call Options Held
6.23M
Put Options Held
2.97M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email